Drug
Tunlametinib clinical trials
Also written HL-085.
- studies test it
- 17
- open now
- 12
- in phase 3
- 2
- first study started
- 2017
Keep track of what changes. Save the tunlametinib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Development codes
Combined with it in one product
Studies by the year they started
16 studies that test it; most in 2026 (4); 1 more planned to start later
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 3 |
| 2021 | 2 |
| 2023 | 3 |
| 2025 | 1 |
| 2026 | 4 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 5
- Phase 2
- 10
- Phase 3
- 2
- Phase 4
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 11 · Other 6
Shanghai Kechow Pharma, Inc. (10) · Sun Yat-sen University (2) · Fudan University (2) · Kechow Pharma, Inc. (1) · Chinese PLA General Hospital (1) · Tianjin Medical University Second Hospital (1)
Often tested with
Tested in the same studies.
Vemurafenib (4) · Proteasomal Ubiquitin Receptor ADRM1 (1) · Fulzerasib (1) · Nimotuzumab (1) · Pucotenlimab (1) · Hydroxychloroquine (1) · Docetaxel (1)
Studies
Open first, then newest update. How each study uses tunlametinib is read from its arms, and is right about nine times in ten.
Testing it · 17
- Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal CancerRecruitingPhase 3Shanghai Kechow Pharma, Inc.NCT06008119Written as Tunlametinib plus Vemurafenib
- Tunlametinib in Combination With Pucotenlimab and Hydroxychloroquine in NRAS Mutant MelanomaRecruitingPhase 2Sun Yat-sen UniversityNCT07750067Written as Tunlametinib
- Tunlametinib Combination Therapy in KRAS-Mutated Unresectable Locally Advanced or Metastatic Non-Small Cell Lung CancerNot yet recruitingPhase 2Sun Yat-sen UniversityNCT07463677Written as Tunlametinib + Fulzerasib
- Efficacy of Tunlametinib in Combination With Anti-EGFR Monoclonal Antibody in Patients With RAS-Mutated Advanced Gastrointestinal MalignanciesNot yet recruitingPhase 2Chinese PLA General HospitalNCT07446270Written as Pancreatic cancer: Tunlametinib +Nimotuzumab
- RWS of Tunlametinib in NRAS-Mutant Advanced MelanomaRecruitingPhase 4Fudan UniversityNCT07445022Written as tunlametinib
- Phase II Trial of Tunlametinib in Patients With NRAS Mutant Non-melanoma Refractory Solid TumorsRecruitingPhase 2Tianjin Medical University Second HospitalNCT07170293Written as Tunlametinib
- Phase II Trial of Tunlametinib in NRAS-Mutant Advanced Thyroid CancerRecruitingPhase 2Fudan UniversityNCT06970353Written as Tunlametinib
- Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant MelanomaRecruitingPhase 3Shanghai Kechow Pharma, Inc.NCT06008106Written as tunlametinib
- Efficacy and Safety of HL-085 Combined With Vemurafenib in BRAF V600E Patients With Non-small Cell Lung Cancer: a Phase II Clinical StudyNot yet recruitingPhase 2Shanghai Kechow Pharma, Inc.NCT05900219Written as HL-085+Vemurafenib
- A PhaseI Study of HL-085 Plus Vemurafenib in Solid Tumor With BRAF V600 MutationRecruitingPhase 1Shanghai Kechow Pharma, Inc.NCT03781219Written as HL-085
- HL-085 in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform NeurofibromasRecruitingPhase 2Shanghai Kechow Pharma, Inc.NCT05331105Written as HL-085
- HL-085+Vemurafenib to Treat Advanced Melanoma Patients With BRAF V600E/K MutationRecruitingPhase 2Shanghai Kechow Pharma, Inc.NCT05263453Written as HL-085
- Study of HL-085 in NRAS Mutant Advanced MelanomaCompletedPhase 1/2Shanghai Kechow Pharma, Inc.NCT03973151Written as HL-085
- HL-085 in NRAS-mutated Advanced MelanomaCompletedPhase 2Shanghai Kechow Pharma, Inc.NCT05217303Written as HL-085
- Study of HL-085 in Patients With Advanced Solid Tumor TumorsCompletedPhase 1Kechow Pharma, Inc.NCT04683354Written as HL-085
- Study of HL-085 Plus Docetaxel in Patients With KRAS Mutant NSCLCTerminatedPhase 1Shanghai Kechow Pharma, Inc.NCT03990077Written as HL-085
- Phase I Study of HL-085 in Patients With Advanced Solid TumorsTerminatedPhase 1Shanghai Kechow Pharma, Inc.NCT03976050Written as HL-085
Given in every arm · 1 — tunlametinib is usual care beside what is tested
Codes
What other systems call tunlametinib · ClinicalTrials.gg INT016851
- UNII (FDA) IF25NR1PV3TUNLAMETINIBConfirmed FDA, Wikidata
- Wikidata Q130282613tunlametinibConfirmed FDA, Wikidata
- NCI Thesaurus C173437TunlametinibOne source FDA
- DrugBank DB18791One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | IF25NR1PV3 | TUNLAMETINIB | Confirmed FDA, Wikidata |
| Wikidata | Q130282613 | tunlametinib | Confirmed FDA, Wikidata |
| NCI Thesaurus | C173437 | Tunlametinib | One source FDA |
| DrugBank | DB18791 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.